Using preoperative radiotherapy and surgery for treating soft tissue sarcoma in limbs
Official title: Safety and Efficacy of Preoperative Stereotactic Body Radiotherapy (SBRT) and Radical Surgery for Soft Tissue Sarcoma of Extremities
Run by Second Affiliated Hospital, Zhejiang University, School of Medicine · NCT06760221 · Data updated 2026-11-12
This study is testing if giving radiation therapy before surgery can help people with large or difficult-to-remove soft tissue tumors in their arms or legs feel better and have better outcomes.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years to 80 Years |
| Sex | All |
| Enrollment | 20 (estimated) |
| Sponsor | Second Affiliated Hospital, Zhejiang University, School of Medicine Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Hangzhou, Zhejiang) |
| Status | Recruiting |
| Started | March 23, 2023 |
| Main results expected | April 1, 2027 |
| Study ends | December 31, 2029 |
| Registry record updated | January 6, 2025 |
| Trial ID | NCT06760221 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults aged 18 and older with confirmed high-grade soft tissue sarcomas that are not amenable to immediate surgery.
✕Probably not a fit
Patients with small, low-grade tumors or those who have already received other antitumor therapies may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This clinical trial investigates the safety and effectiveness of preoperative stereotactic body radiotherapy (SBRT) followed by radical surgery in patients with high-grade soft tissue sarcomas of the extremities. It focuses on tumors larger than 5 cm or those with challenging surgical margins due to nearby blood vessels or nerves. The study is designed as a multicenter, prospective, single-arm trial, aiming to assess surgical safety, quality of life, and tumor control outcomes. Participants will undergo SBRT before surgery to optimize treatment efficacy and minimize risks.
Why it matters
Potential benefit: If successful, this approach could improve surgical outcomes and quality of life for patients with high-grade soft tissue sarcomas.
How similar studies have gone: While the effectiveness of preoperative SBRT is still being evaluated, similar approaches in other studies have shown promising results in improving surgical outcomes.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Aged ≥18 years; 2. Confirmed diagnosis of soft tissue sarcomas; 3. Highly malignant soft tissue sarcomas; 4. Not received surgery, chemotherapy or other antitumor therapy; 5. ECOG (Eastern Cooperative Oncology Group) performance status 0 or 1; 6. Signed informed consent; 7. Willing to provide tissue from an excisional biopsy of a tumor lesion,willing to provide blood sample before and after treatment; Exclusion Criteria: 1. Patients with soft tissue sarcoma of extremities with shallow tumor location, small size, low grade pathology and operable surgical resection; 2. Distant metastasis; 3. Received surgery or chemotherapy or other antitumor therapy; 4. Previously participated in other clinical trials; 5. History of severe allergies, patients with allergic conditions, such as contrast agent allergy; 6. Known additional malignancy that is progressing or requires active treatment. Exceptions include basal cell carcinoma of the skin or squamous cell carcinoma of the skin that has undergone potentially curative therapy, or in situ cervical cancer. 7. Diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy; 8. Active infection requiring systemic therapy; 9. Known psychiatric or substance abuse disorders ; 10. Pregnant or breastfeeding; 11. Known history of human immunodeficiency virus (HIV: HIV 1/2 antibodies); 12. Received a live vaccine within 30 days before radiotherapy. 13. Unable to lie flat.
Where it's running
-
the second affiliated hospital of Zhejiang University Hangzhou, Zhejiang, China, 310009
Hangzhou, Zhejiang, China Recruiting
Study contacts
- Principal investigator: Qichun Wei, MD/PhD — Zhejiang University
- Study coordinator: Haiyan Chen, MD/PhD
- Email: chenhaiyan@zju.edu.cn
- Phone: +8657187783521
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
68Ga-HX01 PET/CT Imaging in Soft Tissue Sarcoma patients
This study tests whether a 68Ga-HX01 injection can help PET/CT imaging better characterize soft tissue sarcoma in adults who have exhausted standard treatments or have no good options.
-
Zemetostat plus Anlotinib for SWI/SNF-deficient Head and Neck Soft Tissue Sarcoma
This trial tests whether zemetostat plus anlotinib can help people with recurrent or metastatic head-and-neck soft tissue sarcoma that has SWI/SNF complex deficiency after standard therapy fails.
-
Entinostat for pediatric soft tissue sarcoma with PAX abnormalities
This study tests entinostat, alone or with chemotherapy, in children whose soft tissue sarcomas have PAX-family gene abnormalities to see if it can help shrink tumors or slow progression.
-
Methionine-Reduced Diet in Solid Tumors (early-phase)
A small pilot study will test whether a methionine-reduced diet can change blood levels in adults with various solid tumors who are receiving standard cancer therapy.
-
Preoperative Immunonutrition for bone and soft tissue sarcoma patients
This study tests whether a short course of an oral nutrition supplement before surgery can help patients with bone or soft tissue sarcomas recover better after major tumor-related surgery.
-
Adaptive Proton Therapy for Pediatric Solid Tumors and Hodgkin Lymphoma
This study tests a regular imaging approach to see if proton therapy plans for children with solid tumors or Hodgkin lymphoma should be updated during treatment.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.